Zhang Yan-Xi, Hu Hai-Sheng, Sun Bao-Qing
Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou 510120, Guangdong Province, China.
World J Cardiol. 2024 Oct 26;16(10):611-615. doi: 10.4330/wjc.v16.i10.611.
We comment on an article by Grubić Rotkvić published in the recent issue of the . We specifically focused on possible factors affecting the therapeutic effectiveness of sodium-dependent glucose transporter inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and their impact on comorbidities. SGLT2i inhibits SGLT2 in the proximal tubules of the kidneys, lowering blood glucose levels by inhibiting glucose reabsorption by the kidneys and causing excess glucose to be excreted in the urine. Previous studies have demonstrated a role of SGLT2i in cardiovascular function in patients with diabetes who take metformin but still have poor glycemic control. In addition, SGLT2i has been shown to be effective in anti-apoptosis, weight loss, and cardiovascular protection. Accordingly, it is feasible to treat patients with T2DM with cardiovascular or renal diseases using SGLT2i.
我们对Grubić Rotkvić发表在最近一期《 》上的一篇文章进行评论。我们特别关注了影响2型糖尿病（T2DM）患者中钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）治疗效果的可能因素及其对合并症的影响。SGLT2i抑制肾脏近端小管中的SGLT2，通过抑制肾脏对葡萄糖的重吸收来降低血糖水平，并使多余的葡萄糖通过尿液排出。先前的研究已经证明SGLT2i在服用二甲双胍但血糖控制仍不佳的糖尿病患者的心血管功能中发挥作用。此外，SGLT2i已被证明在抗细胞凋亡、体重减轻和心血管保护方面有效。因此，使用SGLT2i治疗患有心血管或肾脏疾病的T2DM患者是可行的。
